Seven Hale is building the definitive end-to-end injectable peptide experience in the United States — from discovery and comparison to pharmacy-compounded, dose-ready delivery.
SelectGLP1
Prium Health
We believe personalized peptide therapy should be safe, transparent, and accessible to everyone. Seven Hale integrates comparison tools, trusted brands, and a licensed compounding pharmacy into a single, vertically integrated platform.
From provider comparison to pharmacy fulfillment, we own every step of the patient journey — eliminating the fragmentation and quality gaps that plague the current market.
Every compound is formulated in our licensed 503A/503B facility under USP 797 and 800 standards, with third-party potency and sterility testing on every batch.
No two patients are the same. Our clinician-guided protocols and pharmacy capabilities enable truly individualized peptide formulations tailored to each patient's needs.
Each brand in the Seven Hale portfolio serves a distinct role in delivering the most trusted, personalized peptide experience in the country.
The most comprehensive GLP-1 and peptide provider comparison platform — helping patients find the right treatment at the right price.
Visit site
Licensed 503A/503B compounding pharmacy specializing in personalized, dose-ready injectable peptide formulations with full traceability.
Visit site
BestGLP1.com, SeniorGLP1.com, PersonalizedPeptides.com, and BestGLP3.com — category-leading comparison destinations across every peptide vertical.
Coming soonIn February 2026, HHS Secretary Kennedy announced that 14 of the 19 peptides on the FDA's Category 2 restricted list will be reclassified back to Category 1, restoring legal compounding access for BPC-157, Thymosin Alpha-1, CJC-1295/Ipamorelin, and AOD-9604 — the largest expansion of compoundable peptide SKUs in over a decade.
Injectable peptide therapy went mainstream in 2025, yet 30% of products currently on the market are mislabeled, underdosed, or contaminated — creating massive whitespace for a trusted, pharmacy-backed brand.
The U.S. peptide therapeutics market sits at $21.2B in 2025, projected to reach $35B by 2035 at a 5.1% CAGR — and that's before the Category 1 reclassification unlocks an entirely new wave of compound pharmacy volume.
Seven Hale powers personalized peptide experiences for premium wellness brands. We provide the clinical infrastructure, pharmacy fulfillment, and regulatory compliance — you provide the brand and the audience.
Email us at partnerships@sevenhale.com to learn more.
"The FDA is weighing broader access to compounded peptides, signaling the largest regulatory shift in personalized therapeutics in a decade."
"An FDA advisory panel is expected to support broader peptide compounding access, opening the door for licensed pharmacies nationwide."
"Injectable peptide therapy went mainstream in 2025, priming consumers for the next big wave in wellness."
We're assembling a team of operators, clinicians, pharmacists, and builders who believe personalized medicine should be the standard — not the exception.